Jonathan Trent, MD, PhD, University of Miami, Miami, FL, gives an overview of results from the Phase III INTRIGUE trial (NCT03673501) of ripretinib in patients with gastrointestinal stromal tumor (GIST). Patients either received ripretinib or sunitinib, and no statistically significant benefit was observed in patients receiving ripretinib. In an analysis of patients who did not have baseline circulating tumor DNA (ctDNA), better efficacy outcomes were reported and patients were younger in age. For this group of patients, ripretinib or sunitinib are both viable treatment options. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
